These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 9816180)

  • 1. PAK-104P, a pyridine analogue, reverses paclitaxel and doxorubicin resistance in cell lines and nude mice bearing xenografts that overexpress the multidrug resistance protein.
    Vanhoefer U; Cao S; Minderman H; Tóth K; Scheper RJ; Slovak ML; Rustum YM
    Clin Cancer Res; 1996 Feb; 2(2):369-77. PubMed ID: 9816180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP).
    Vanhoefer U; Cao S; Harstrick A; Seeber S; Rustum YM
    Ann Oncol; 1997 Dec; 8(12):1221-8. PubMed ID: 9496387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of the P-glycoprotein- and multidrug resistance protein-mediated efflux of anthracyclines and calceinacetoxymethyl ester by PAK-104P.
    Marbeuf-Gueye C; Salerno M; Quidu P; Garnier-Suillerot A
    Eur J Pharmacol; 2000 Mar; 391(3):207-16. PubMed ID: 10729360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of multidrug resistance-associated protein-mediated drug resistance by the pyridine analog PAK-104P.
    Sumizawa T; Chen ZS; Chuman Y; Seto K; Furukawa T; Haraguchi M; Tani A; Shudo N; Akiyama SI
    Mol Pharmacol; 1997 Mar; 51(3):399-405. PubMed ID: 9058594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P.
    Chen ZS; Furukawa T; Sumizawa T; Ono K; Ueda K; Seto K; Akiyama SI
    Mol Pharmacol; 1999 May; 55(5):921-8. PubMed ID: 10220571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal of MRP-mediated vincristine resistance in KB cells by buthionine sulfoximine in combination with PAK-104P.
    Chuman Y; Chen ZS; Seto K; Sumizawa T; Furukawa T; Tani A; Haraguchi M; Niwa K; Yamada K; Aikou T; Akiyama S
    Cancer Lett; 1998 Jul; 129(1):69-76. PubMed ID: 9714337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors.
    Vanhoefer U; Cao S; Minderman H; Toth K; Skenderis BS; Slovak ML; Rustum YM
    Clin Cancer Res; 1996 Dec; 2(12):1961-8. PubMed ID: 9816155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal of LRP-associated drug resistance in colon carcinoma SW-620 cells.
    Kitazono M; Okumura H; Ikeda R; Sumizawa T; Furukawa T; Nagayama S; Seto K; Aikou T; Akiyama S
    Int J Cancer; 2001 Jan; 91(1):126-31. PubMed ID: 11149411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DiOC2(3) is not a substrate for multidrug resistance protein (MRP)-mediated drug efflux.
    Minderman H; Vanhoefer U; Toth K; Yin MB; Minderman MD; Wrzosek C; Slovak ML; Rustum YM
    Cytometry; 1996 Sep; 25(1):14-20. PubMed ID: 8875050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of heavy metal resistance in multidrug-resistant human KB carcinoma cells.
    Chen ZS; Mutoh M; Sumizawa T; Furukawa T; Haraguchi M; Tani A; Akiyama S
    Biochem Biophys Res Commun; 1997 Jul; 236(3):586-90. PubMed ID: 9245693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
    Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclosporin A is a broad-spectrum multidrug resistance modulator.
    Qadir M; O'Loughlin KL; Fricke SM; Williamson NA; Greco WR; Minderman H; Baer MR
    Clin Cancer Res; 2005 Mar; 11(6):2320-6. PubMed ID: 15788683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter.
    Chen ZS; Kawabe T; Ono M; Aoki S; Sumizawa T; Furukawa T; Uchiumi T; Wada M; Kuwano M; Akiyama SI
    Mol Pharmacol; 1999 Dec; 56(6):1219-28. PubMed ID: 10570049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two pyridine analogues with more effective ability to reverse multidrug resistance and with lower calcium channel blocking activity than their dihydropyridine counterparts.
    Shudo N; Mizoguchi T; Kiyosue T; Arita M; Yoshimura A; Seto K; Sakoda R; Akiyama S
    Cancer Res; 1990 May; 50(10):3055-61. PubMed ID: 1970752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carbamoylation of glutathione reductase by N,N-bis(2-chloroethyl)-N- nitrosourea associated with inhibition of multidrug resistance protein (MRP) function.
    Vanhoefer U; Yin MB; Harstrick A; Seeber S; Rustum YM
    Biochem Pharmacol; 1997 Mar; 53(6):801-9. PubMed ID: 9113101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.
    Mistry P; Stewart AJ; Dangerfield W; Okiji S; Liddle C; Bootle D; Plumb JA; Templeton D; Charlton P
    Cancer Res; 2001 Jan; 61(2):749-58. PubMed ID: 11212278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MRP1 modulation by PAK-104P: detection with technetium-99m-MIBI in cultured lung tumor cells.
    Vergote J; Moretti JL; Kouyoumdjian JC; Garnier-Suillerot A
    Anticancer Res; 2002; 22(1A):251-6. PubMed ID: 12017298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP.
    Germann UA; Ford PJ; Shlyakhter D; Mason VS; Harding MW
    Anticancer Drugs; 1997 Feb; 8(2):141-55. PubMed ID: 9073310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of MRP-mediated doxorubicin resistance with quinoline-based drugs.
    Vezmar M; Georges E
    Biochem Pharmacol; 2000 May; 59(10):1245-52. PubMed ID: 10736425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Mechanisms for resistance to anticancer agents and the reversal of the resistance].
    Akiyama S; Chen ZS; Kitazono M; Sumizawa T; Furukawa T; Aikou T
    Hum Cell; 1999 Sep; 12(3):95-102. PubMed ID: 10695015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.